Scribe Therapeutics (SCTX) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 14, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Sep 30, 2026: 1 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about SCTX filings

Are insiders buying or selling Scribe Therapeutics Inc. Common Stock (SCTX) stock?

Neither. Scribe Therapeutics Inc. Common Stock (SCTX) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded SCTX recently?

None. No member of Congress disclosed a SCTX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SCTX smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

BRBlackRockQ3 2026 13FAdded

13F: filed up to 45 days late.

Smart money on SCTX

Lean long1 source:
- Funds

Top traders
No tracked positions at the last update
Insiders
No recent insider filings found
Congress
No recent politician filings found
Funds
- BlackRock, added, holdings at Sep 30
Lean long · thin1 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about SCTX filings

Are insiders buying or selling Scribe Therapeutics Inc. Common Stock (SCTX) stock?

Neither. Scribe Therapeutics Inc. Common Stock (SCTX) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded SCTX recently?

None. No member of Congress disclosed a SCTX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SCTX smart-money data?

Funds

What funds are doing

1 move · 6 mo

Buys/Adds$12.5M

Buys/Adds (1)

BR
BlackRock
Q3 2026 13F
$12.5M
bought
Signals like this: n=3228, 54% finished lower at D15, median -0.8% vs SPY -0.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 12, 2026

Earnings came in 34.0% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 12, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.68+33.98% beat

-$1.03 expected

Revenue

$1.6M

SEC filing

EPS: Yahoo Finance

Next report

Estimated report: Dec 2, 2026, in 18 days

Estimates as of Nov 13, 2026

EPS expected

-$1.03

-$1.46 to -$0.75

Revenue expected

$3.7M

5 analysts

Estimate drift

1.03

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 12, 2026	-$0.68est. -$1.03	+33.98%beat	$1.6MSEC filing	-91.9%from $20.1M
Jun 30, 2026Reported Sep 2, 2026	-$2.62est. -$3.72	+29.51%beat	$1.9MSEC filing	-60.8%from $4.9M
Sep 30, 2025Reported Nov 12, 2026	Not on file	No estimate	$20.1MSEC filing	No year-ago quarter
Jun 30, 2025Reported Sep 2, 2026	Not on file	No estimate	$4.9MSEC filing	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $16.37
High: $17.49
Low: $15.55
Prev close: $16.86
52-wk high: $39.60
52-wk low: $13.50
Mkt cap: $319.2M
ROE: +0.0%
P/S: 9.6x
Profit margin: -97.0%
Op margin: -92.2%

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -97.0%
Market cap: $319M

Valuation

P/S9.58

Quality

Operating margin-92.2%
ROE0.0%
ROA0.0%

Growth

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

15 / 100

RSI 14

58balanced

20D volatility

97%annualized

52-week range

$16.99

$13.50$39.60

20D support

$14.29recent floor

20D resistance

$21.37recent ceiling

Returns

5D +9.8%20D -18.0%60D -45.3%

Price vs moving averages

SMA20 -0.5%SMA50 -20.7%

Volume pace

0.60xvs prior 20D

Smart money at a glance

Filings to Nov 14, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Sep 30, 2026: 1 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about SCTX filings

Are insiders buying or selling Scribe Therapeutics Inc. Common Stock (SCTX) stock?

Neither. Scribe Therapeutics Inc. Common Stock (SCTX) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded SCTX recently?

None. No member of Congress disclosed a SCTX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SCTX smart-money data?

BRBlackRockQ3 2026 13FAdded

13F: filed up to 45 days late.

Smart money on SCTX

Lean long1 source:
- Funds

Top traders
No tracked positions at the last update
Insiders
No recent insider filings found
Congress
No recent politician filings found
Funds
- BlackRock, added, holdings at Sep 30
Lean long · thin1 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about SCTX filings

Are insiders buying or selling Scribe Therapeutics Inc. Common Stock (SCTX) stock?

Neither. Scribe Therapeutics Inc. Common Stock (SCTX) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded SCTX recently?

None. No member of Congress disclosed a SCTX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this SCTX smart-money data?

Funds

What funds are doing

1 move · 6 mo

Buys/Adds$12.5M

Buys/Adds (1)

BR
BlackRock
Q3 2026 13F
$12.5M
bought
Signals like this: n=3228, 54% finished lower at D15, median -0.8% vs SPY -0.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 12, 2026

Earnings came in 34.0% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 12, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.68+33.98% beat

-$1.03 expected

Revenue

$1.6M

SEC filing

EPS: Yahoo Finance

Next report

Estimated report: Dec 2, 2026, in 18 days

Estimates as of Nov 13, 2026

EPS expected

-$1.03

-$1.46 to -$0.75

Revenue expected

$3.7M

5 analysts

Estimate drift

1.03

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 12, 2026	-$0.68est. -$1.03	+33.98%beat	$1.6MSEC filing	-91.9%from $20.1M
Jun 30, 2026Reported Sep 2, 2026	-$2.62est. -$3.72	+29.51%beat	$1.9MSEC filing	-60.8%from $4.9M
Sep 30, 2025Reported Nov 12, 2026	Not on file	No estimate	$20.1MSEC filing	No year-ago quarter
Jun 30, 2025Reported Sep 2, 2026	Not on file	No estimate	$4.9MSEC filing	No year-ago quarter

Open: $16.37
High: $17.49
Low: $15.55
Prev close: $16.86
52-wk high: $39.60
52-wk low: $13.50
Mkt cap: $319.2M
ROE: +0.0%
P/S: 9.6x
Profit margin: -97.0%
Op margin: -92.2%

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -97.0%
Market cap: $319M

Valuation

P/S9.58

Quality

Operating margin-92.2%
ROE0.0%
ROA0.0%

Growth

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

15 / 100

RSI 14

58balanced

20D volatility

97%annualized

52-week range

$16.99

$13.50$39.60

20D support

$14.29recent floor

20D resistance

$21.37recent ceiling

Returns

5D +9.8%20D -18.0%60D -45.3%

Price vs moving averages

SMA20 -0.5%SMA50 -20.7%

Volume pace

0.60xvs prior 20D

Scribe Therapeutics Inc. Common Stock

Smart money at a glance

What do analysts expect?

Questions about SCTX filings

Smart money on SCTX

Questions about SCTX filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 34.0% above what analysts expected.

Estimated report: Dec 2, 2026, in 18 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Scribe Therapeutics Inc. Common Stock

Smart money at a glance

What do analysts expect?

Questions about SCTX filings

Smart money on SCTX

Questions about SCTX filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 34.0% above what analysts expected.

Estimated report: Dec 2, 2026, in 18 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Scribe Therapeutics Inc. Common Stock

Overview

Questions about SCTX filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Scribe Therapeutics Inc. Common Stock

Overview

Questions about SCTX filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.